Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other financing activities (2021 - 2025)

Historic Other financing activities for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to $164000.0.

  • C4 Therapeutics' Other financing activities fell 4478.11% to $164000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $382000.0, marking a year-over-year decrease of 1784.95%. This contributed to the annual value of $382000.0 for FY2024, which is 380.43% up from last year.
  • C4 Therapeutics' Other financing activities amounted to $164000.0 in Q3 2025, which was down 4478.11% from $109000.0 recorded in Q1 2025.
  • Over the past 5 years, C4 Therapeutics' Other financing activities peaked at $297000.0 during Q3 2024, and registered a low of -$286000.0 during Q4 2021.
  • For the 5-year period, C4 Therapeutics' Other financing activities averaged around $91714.3, with its median value being $106500.0 (2023).
  • In the last 5 years, C4 Therapeutics' Other financing activities soared by 743333.33% in 2022 and then crashed by 5272.73% in 2023.
  • Over the past 5 years, C4 Therapeutics' Other financing activities (Quarter) stood at -$286000.0 in 2021, then surged by 152.45% to $150000.0 in 2022, then tumbled by 100.67% to -$1000.0 in 2023, then surged by 200.0% to $1000.0 in 2024, then skyrocketed by 16300.0% to $164000.0 in 2025.
  • Its last three reported values are $164000.0 in Q3 2025, $109000.0 for Q1 2025, and $1000.0 during Q4 2024.